DOCSLIB.ORG

Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use THE NATIONAL ACADEMIES PRESS This PDF is available at http://www.nap.edu/24781 SHARE Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use DETAILS 482 pages | 6 x 9 | PAPERBACK ISBN 978-0-309-45954-9 | DOI: 10.17226/24781 CONTRIBUTORS GET THIS BOOK Richard J. Bonnie, Morgan A. Ford, and Jonathan K. Phillips, Editors; Committee on Pain Management and Regulatory Strategies to Address Prescription Opioid Abuse; Board on Health Sciences FIND RELATED TITLES Policy; Health and Medicine Division; National Academies of Sciences, Engineering, and Medicine Visit the National Academies Press at NAP.edu and login or register to get: – Access to free PDF downloads of thousands of scientific reports – 10% off the price of print titles – Email or social media notifications of new titles related to your interests – Special offers and discounts Distribution, posting, or copying of this PDF is strictly prohibited without written permission of the National Academies Press. (Request Permission) Unless otherwise indicated, all materials in this PDF are copyrighted by the National Academy of Sciences. Copyright © National Academy of Sciences. All rights reserved. Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use Committee on Pain Management and Regulatory Strategies to Address Prescription Opioid Abuse Richard J. Bonnie, Morgan A. Ford, and Jonathan K. Phillips, Editors Board on Health Sciences Policy Health and Medicine Division A Consensus Study Report of Copyright © National Academy of Sciences. All rights reserved. Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use THE NATIONAL ACADEMIES PRESS 500 Fifth Street, NW Washington, DC 20001 This activity was supported by Grant No. HHSF223201610015C from the U.S. Food and Drug Administration. Any opinions, findings, conclusions, or recom- mendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project. International Standard Book Number-13: 978-0-309-45954-9 International Standard Book Number-10: 0-309-45954-0 Digital Object Identifier: https://doi.org/10.17226/24781 Library of Congress Control Number: 2017950552 Additional copies of this publication are available for sale from the National Acad- emies Press, 500 Fifth Street, NW, Keck 360, Washington, DC 20001; (800) 624- 6242 or (202) 334-3313; http://www.nap.edu. Copyright 2017 by the National Academy of Sciences. All rights reserved. Printed in the United States of America Suggested citation: National Academies of Sciences, Engineering, and Medicine. 2017. Pain management and the opioid epidemic: Balancing societal and individual benefits and risks of prescription opioid use. Washington, DC: The National Acad- emies Press. doi: https://doi.org/10.17226/24781. Copyright © National Academy of Sciences. All rights reserved. Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use The National Academy of Sciences was established in 1863 by an Act of Con- gress, signed by President Lincoln, as a private, nongovernmental institution to advise the nation on issues related to science and technology. Members are elected by their peers for outstanding contributions to research. Dr. Marcia McNutt is president. The National Academy of Engineering was established in 1964 under the char- ter of the National Academy of Sciences to bring the practices of engineering to advising the nation. Members are elected by their peers for extraordinary contributions to engineering. Dr. C. D. Mote, Jr., is president. The National Academy of Medicine (formerly the Institute of Medicine) was established in 1970 under the charter of the National Academy of Sciences to advise the nation on medical and health issues. Members are elected by their peers for distinguished contributions to medicine and health. Dr. Victor J. Dzau is president. The three Academies work together as the National Academies of Sciences, Engi neering, and Medicine to provide independent, objective analysis and ad- vice to the nation and conduct other activities to solve complex problems and inform public policy decisions. The National Academies also encourage education and research, recognize outstanding contributions to knowledge, and increase public understanding in matters of science, engineering, and medicine. Learn more about the National Academies of Sciences, Engineering, and Medi- cine at www.nationalacademies.org. Copyright © National Academy of Sciences. All rights reserved. Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use Consensus Study Reports published by the National Academies of Sciences, Engineering, and Medicine document the evidence-based consensus on the study’s statement of task by an authoring committee of experts. Reports typi- cally include findings, conclusions, and recommendations based on information gathered by the committee and the committee’s deliberations. Each report has been subjected to a rigorous and independent peer-review process and it represents the position of the National Academies on the statement of task. Proceedings published by the National Academies of Sciences, Engineering, and Medicine chronicle the presentations and discussions at a workshop, symposium, or other event convened by the National Academies. The statements and opin- ions contained in proceedings are those of the participants and are not endorsed by other participants, the planning committee, or the National Academies. For information about other products and activities of the National Academies, please visit www.nationalacademies.org/about/whatwedo. Copyright © National Academy of Sciences. All rights reserved. Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use COMMITTEE ON PAIN MANAGEMENT AND REGULATORY STRATEGIES TO ADDRESS PRESCRIPTION OPIOID ABUSE RICHARD J. BONNIE (Chair), Harrison Foundation Professor of Medicine and Law; Director, Institute of Law, Psychiatry and Public Policy, University of Virginia School of Law, Charlottesville HORTENSIA DE LOS ANGELES AMARO, Associate Vice Provost for Community Research Initiatives; Dean’s Professor of Social Work and Preventive Medicine, School of Social Work, University of Southern California, Los Angeles LINDA BURNES BOLTON, System Chief Nurse Executive; Vice President, Nursing; Chief Nursing Officer, Cedars-Sinai Medical Center, Los Angeles, California JONATHAN P. CAULKINS, H. Guyford Stever Professor of Operations Research and Public Policy, Heinz School of Public Policy and Management, Carnegie Mellon University, Pittsburgh, Pennsylvania DAVID CLARK, Professor of Anesthesia, Perioperative Pain Medicine and Pain, Stanford University; Director, Veterans Affairs Pain Clinic, Palo Alto, California ELI ELIAV, Professor and Director, Eastman Institute for Oral Health; Vice Dean for Oral Health, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, New York GARRET FITZGERALD, McNeil Professor in Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia TRACI C. GREEN, Deputy Director, Injury Prevention Center, Boston Medical Center, Boston University School of Medicine, Massachusetts; Associate Professor of Emergency Medicine and Epidemiology, The Warren Alpert School of Medicine, Brown University, Providence, Rhode Island MIGUEL HERNÁN, Kolokotrones Professor of Biostatistics and Epidemiology, Harvard T.H. Chan School of Public Health; Harvard- Massachusetts Institute of Technology Division of Health Sciences and Technology, Boston, Massachusetts LEE D. HOFFER, Associate Professor, Department of Anthropology, Case Western Reserve University, Cleveland, Ohio PAUL E. JARRIS, Senior Vice President of Maternal and Child Health Program Impact; Deputy Medical Director, March of Dimes Foundation, Washington, DC KAROL KALTENBACH, Emeritus Professor of Pediatrics, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania v Copyright © National Academy of Sciences. All rights reserved. Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use AARON S. KESSELHEIM, Associate Professor of Medicine, Harvard Medical School; Director, Program On Regulation, Therapeutics, And Law (PORTAL), Brigham and Women’s Hospital, Boston, Massachusetts ANNE MARIE MCKENZIE-BROWN, Associate Professor of Anesthesiology; Director, Division of Pain Management, Emory University School of Medicine, Atlanta, Georgia JOSE MORON-CONCEPCION, Associate Professor of Anesthesiology, School of Medicine, Washington University, St. Louis, Missouri A. DAVID PALTIEL, Professor, Department of Health Policy and Management, School of Public Health, School of Management, Yale University, New Haven, Connecticut VALERIE REYNA, Professor of Human Development; Director, Human Neuroscience Institute, Cornell University, Ithaca, New York MARK SCHUMACHER, Chief, Division of Pain Medicine; Professor of Anesthesiology, School of Medicine, University of California, San Francisco Study Staff MORGAN A. FORD, Study Director JONATHAN K. PHILLIPS, Associate Program Officer ANNE CLAIBORNE, Senior Program Officer CLARE STROUD, Senior Program Officer
Load more

Recommended publications
  • Opioids and Nicotine Dependence in Planarians
    Pharmacology, Biochemistry and Behavior 112 (2013) 9–14 Contents lists available at ScienceDirect Pharmacology, Biochemistry and Behavior journal homepage: www.elsevier.com/locate/pharmbiochembeh Opioid receptor types involved in the development of nicotine physical dependence in an invertebrate (Planaria)model Robert B. Raffa a,⁎, Steve Baron a,b, Jaspreet S. Bhandal a,b, Tevin Brown a,b,KevinSongb, Christopher S. Tallarida a,b, Scott M. Rawls b a Department of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, PA, USA b Department of Pharmacology & Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA, USA article info abstract Article history: Recent data suggest that opioid receptors are involved in the development of nicotine physical dependence Received 18 May 2013 in mammals. Evidence in support of a similar involvement in an invertebrate (Planaria) is presented using Received in revised form 18 September 2013 the selective opioid receptor antagonist naloxone, and the more receptor subtype-selective antagonists CTAP Accepted 21 September 2013 (D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH )(μ, MOR), naltrindole (δ, DOR), and nor-BNI (norbinaltorphimine) Available online 29 September 2013 2 (κ, KOR). Induction of physical dependence was achieved by 60-min pre-exposure of planarians to nicotine and was quantified by abstinence-induced withdrawal (reduction in spontaneous locomotor activity). Known MOR Keywords: Nicotine and DOR subtype-selective opioid receptor antagonists attenuated the withdrawal, as did the non-selective Abstinence antagonist naloxone, but a KOR subtype-selective antagonist did not. An involvement of MOR and DOR, but Withdrawal not KOR, in the development of nicotine physical dependence or in abstinence-induced withdrawal was thus Physical dependence demonstrated in a sensitive and facile invertebrate model.
    [Show full text]
  • Kappa Opioid Regulation of Depressive-Like Behavior During Acute Withdrawal and Protracted Abstinence from Ethanol Sorscha K
    Grand Valley State University ScholarWorks@GVSU Funded Articles Open Access Publishing Support Fund 9-2018 Kappa Opioid Regulation of Depressive-Like Behavior During Acute Withdrawal and Protracted Abstinence from Ethanol Sorscha K. Jarman Grand Valley State University, [email protected] Alison M. Haney Grand Valley State University, [email protected] Glenn R. Valdez Grand Valley State University, [email protected] Follow this and additional works at: https://scholarworks.gvsu.edu/oapsf_articles Part of the Chemicals and Drugs Commons ScholarWorks Citation Jarman, Sorscha K.; Haney, Alison M.; and Valdez, Glenn R., "Kappa Opioid Regulation of Depressive-Like Behavior During Acute Withdrawal and Protracted Abstinence from Ethanol" (2018). Funded Articles. 106. https://scholarworks.gvsu.edu/oapsf_articles/106 This Article is brought to you for free and open access by the Open Access Publishing Support Fund at ScholarWorks@GVSU. It has been accepted for inclusion in Funded Articles by an authorized administrator of ScholarWorks@GVSU. For more information, please contact [email protected]. RESEARCH ARTICLE Kappa opioid regulation of depressive-like behavior during acute withdrawal and protracted abstinence from ethanol ¤ Sorscha K. Jarman, Alison M. Haney , Glenn R. ValdezID* Department of Psychology, Grand Valley State University, Allendale, MI, United States of America ¤ Current address: Department of Psychology, Purdue University, West Lafayette, IN, United States of America * [email protected] a1111111111 a1111111111 a1111111111 a1111111111 Abstract a1111111111 The dynorphin/kappa opioid receptor (DYN/KOR) system appears to be a key mediator of the behavioral effects of chronic exposure to alcohol. Although KOR opioid receptor antago- nists have been shown to decrease stress-related behaviors in animal models during acute ethanol withdrawal, the role of the DYN/KOR system in regulating long-term behavioral OPEN ACCESS changes following protracted abstinence from ethanol is not well understood.
    [Show full text]
  • Datasheet Inhibitors / Agonists / Screening Libraries a DRUG SCREENING EXPERT
    Datasheet Inhibitors / Agonists / Screening Libraries A DRUG SCREENING EXPERT Product Name : Norbinaltorphimine dihydrochloride Catalog Number : T12241 CAS Number : 113158-34-2 Molecular Formula : C40H45Cl2N3O6 Molecular Weight : 734.71 Description: Norbinaltorphimine dihydrochloride is a potent and selective antagonist of κ opioid receptor. Storage: 2 years -80°C in solvent; 3 years -20°C powder; Receptor (IC50) κ opioid receptor In vivo Activity The KOR antagonist, Norbinaltorphimine(norBNI), had weak and inconsistent effects on THC-induced taste avoidance in adolescent rats in that norBNI both attenuated and strengthened taste avoidance dependent on dose and trial. norBNI had limited impact on the final one-bottle avoidance and no effects on the two-bottle preference test. Interestingly, norBNI had no effect on THC-induced taste avoidance in adult rats as well. Reference 1. Flax SM, et al. Effect of norbinaltorphimine on ∆⁹-tetrahydrocannabinol (THC)-induced taste avoidance in adolescent and adult Sprague-Dawley rats. Psychopharmacology (Berl). 2015 Sep;232(17):3193-201. 2. Jackson KJ, et al. Effects of the kappa opioid receptor antagonist, norbinaltorphimine, on stress and drug-induced reinstatement of nicotine-conditioned place preference in mice. Psychopharmacology (Berl). 2013 Apr;226(4):763-8. FOR RESEARCH PURPOSES ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE. Information for product storage and handling is indicated on the product datasheet. Targetmol products are stable for long term under the recommended storage conditions. Our products may be shipped under different conditions as many of them are stable in the short-term at higher or even room temperatures. We ensure that the product is shipped under conditions that will maintain the quality of the reagents.
    [Show full text]
  • NIDA Drug Supply Program Catalog, 25Th Edition
    RESEARCH RESOURCES DRUG SUPPLY PROGRAM CATALOG 25TH EDITION MAY 2016 CHEMISTRY AND PHARMACEUTICS BRANCH DIVISION OF THERAPEUTICS AND MEDICAL CONSEQUENCES NATIONAL INSTITUTE ON DRUG ABUSE NATIONAL INSTITUTES OF HEALTH DEPARTMENT OF HEALTH AND HUMAN SERVICES 6001 EXECUTIVE BOULEVARD ROCKVILLE, MARYLAND 20852 160524 On the cover: CPK rendering of nalfurafine. TABLE OF CONTENTS A. Introduction ................................................................................................1 B. NIDA Drug Supply Program (DSP) Ordering Guidelines ..........................3 C. Drug Request Checklist .............................................................................8 D. Sample DEA Order Form 222 ....................................................................9 E. Supply & Analysis of Standard Solutions of Δ9-THC ..............................10 F. Alternate Sources for Peptides ...............................................................11 G. Instructions for Analytical Services .........................................................12 H. X-Ray Diffraction Analysis of Compounds .............................................13 I. Nicotine Research Cigarettes Drug Supply Program .............................16 J. Ordering Guidelines for Nicotine Research Cigarettes (NRCs)..............18 K. Ordering Guidelines for Marijuana and Marijuana Cigarettes ................21 L. Important Addresses, Telephone & Fax Numbers ..................................24 M. Available Drugs, Compounds, and Dosage Forms ..............................25
    [Show full text]
  • Abstract Book 2012.Indd
    SUPPLEMENT TO JOURNAL OF PSYCHOPHARMACOLOGY VOL 26, SUPPLEMENT TO ISSUE 8, AUGUST 2012 These papers were presented at the Summer Meeting of the BRITISH ASSOCIATION FOR PSYCHOPHARMACOLOGY 22 – 25 July, Harrogate, UK Indemnity The scientific material presented at this meeting reflects the opinions of the contributing authors and speakers. The British Association for Psychopharmacology accepts no responsibility for the contents of the verbal or any published proceedings of this meeting. BAP OFFICE 36 Cambridge Place Hills Road Cambridge CB2 1NS bap.org.uk Aii CONTENTS Abstract Book 2012 Abstracts begin on page: SYMPOSIUM 1 A1 Drugs as tools in neuropsychiatry: Ketamine (S01-S04) SYMPOSIUM 2 A2 New tricks for old drugs: Opiates, addiction and beyond (S05-S08) SYMPOSIUM 3 A3 Advances in understanding brain corticosteroid responses to stress: relevance to depression (S09-S12) SYMPOSIUM 4 A5 Cognitive impairment in depression: A target for treatment? (S13-S16) SYMPOSIUM 5 A6 New treatment strategies for targeting drug addictions – A translational perspective (S17-S20) SYMPOSIUM 6 A7 Functional imaging markers for monitoring treatment: Mechanisms and efficacy (S21-S24) SYMPOSIUM 7 A9 Schizophrenia Treatment: What’s wrong with it and what might work better (S25-S28) SYMPOSIUM 8 A10 Epigenetics and psychiatry - current understanding and therapeutic potential (S29-S32) SYMPOSIUM 9 A11 Rethinking the compulsive aspects of addiction: From bench to bedside (S33-S36) POSTERS Anxiety 1 (MA01-MA07) A13 Affective Disorders 1 (MB01-MB20) A16 Brain Imaging
    [Show full text]
  • Cannabinoid Receptors and Pain
    Progress in Neurobiology 63 (2001) 569–611 www.elsevier.com/locate/pneurobio Cannabinoid receptors and pain Roger G. Pertwee * Department of Biomedical Sciences, Institute of Medical Sciences, Uni6ersity of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, Scotland, UK Received 9 February 2000 Abstract Mammalian tissues contain at least two types of cannabinoid receptor, CB1 and CB2, both coupled to G proteins. CB1 receptors are expressed mainly by neurones of the central and peripheral nervous system whereas CB2 receptors occur centrally and peripherally in certain non-neuronal tissues, particularly in immune cells. The existence of endogenous ligands for cannabinoid receptors has also been demonstrated. The discovery of this ‘endocannabinoid system’ has prompted the development of a range of novel cannabinoid receptor agonists and antagonists, including several that show marked selectivity for CB1 or CB2 receptors. It has also been paralleled by a renewed interest in cannabinoid-induced antinociception. This review summarizes current knowledge about the ability of cannabinoids to produce antinociception in animal models of acute pain as well as about the ability of these drugs to suppress signs of tonic pain induced in animals by nerve damage or by the injection of an inflammatory agent. Particular attention is paid to the types of pain against which cannabinoids may be effective, the distribution pattern of cannabinoid receptors in central and peripheral pain pathways and the part that these receptors play in cannabinoid-induced antinociception. The possibility that antinociception can be mediated by cannabinoid receptors other than CB1 and CB2 receptors, for example CB2-like receptors, is also discussed as is the evidence firstly that one endogenous cannabinoid, anandamide, produces antinociception through mechanisms that differ from those of other types of cannabinoid, for example by acting on vanilloid receptors, and secondly that the endocannabinoid system has physiological and/or pathophysiological roles in the modulation of pain.
    [Show full text]
  • Risk Assessment Report on a New Psychoactive Substance: N-Phenyl- N-[1-(2-Phenylethyl)Piperidin-4-Yl]Furan-2-Carboxamide (Furanylfentanyl)
    This document is being made available in advance of formal layout. It will be replaced with a final version in the formal EMCDDA layout in due course. Risk assessment report on a new psychoactive substance: N-phenyl- N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide (furanylfentanyl) In accordance with Article 6 of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances Risk assessment report on a new psychoactive substance: N- phenyl -N -[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide (furanylfentanyl) In accordance with Article 6 of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances Contents 1. Introduction ........................................................................................................................ 3 2. Physical, chemical and pharmacological description .......................................................... 5 3. Chemical precursors that are used for the manufacture ................................................... 10 4. Health risks ...................................................................................................................... 11 5. Social risks ...................................................................................................................... 18 6. Information on manufacturing, trafficking, distribution, and the level of involvement of organised crime ..............................................................................................................
    [Show full text]
  • Salvinorin a Analogues PR37 and PR38 Attenuate Compound 48
    British Journal of DOI:10.1111/bph.13212 www.brjpharmacol.org BJP Pharmacology RESEARCH PAPER Correspondence Jakub Fichna, Department of Biochemistry, Faculty of Medicine, Medical University of Salvinorin A analogues Lodz, Mazowiecka 6/8, 92-215 Lodz, Poland. E-mail: jakub.fi[email protected] PR-37 and PR-38 attenuate ---------------------------------------------------------------- Received 18 January 2015 compound 48/80-induced Revised 26 May 2015 Accepted itch responses in mice 1 June 2015 M Salaga1, P R Polepally2, M Zielinska1, M Marynowski1, A Fabisiak1, N Murawska1, K Sobczak1, M Sacharczuk3,JCDoRego4, B L Roth5, J K Zjawiony2 and J Fichna1 1Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Lodz, Poland, 2Department of BioMolecular Sciences, Division of Pharmacognosy and Research Institute of Pharmaceutical Sciences, School of Pharmacy, University of Mississippi, University, MS, USA, 3Department of Molecular Cytogenetic, Institute of Genetics and Animal Breeding, Polish Academy of Sciences, Jastrzebiec, Poland, 4Platform of Behavioural Analysis (SCAC), Institute for Research and Innovation in Biomedicine (IRIB), Faculty of Medicine & Pharmacy, University of Rouen, Rouen Cedex, France, and 5Department of Pharmacology, Division of Chemical Biology and Medicinal Chemistry, Medical School, NIMH Psychoactive Drug Screening Program, University of North Carolina, Chapel Hill, NC, USA BACKGROUND AND PURPOSE The opioid system plays a crucial role in several physiological processes in the CNS and in the periphery. It has also been shown that selective opioid receptor agonists exert potent inhibitory action on pruritus and pain. In this study we examined whether two analogues of Salvinorin A, PR-37 and PR-38, exhibit antipruritic properties in mice. EXPERIMENTAL APPROACH To examine the antiscratch effect of PR-37 and PR-38 we used a mouse model of compound 48/80-induced pruritus.
    [Show full text]
  • Kappa-Opioid Receptor Modulation of Nicotine-Induced Behaviour B
    Neuropharmacology 39 (2000) 2848–2855 www.elsevier.com/locate/neuropharm Kappa-opioid receptor modulation of nicotine-induced behaviour B. Hahn *, I.P. Stolerman, M. Shoaib Section of Behavioural Pharmacology, Institute of Psychiatry, De Crespigny Park, London SE5 8AF, UK Accepted 4 July 2000 Abstract The ability of ␬-opioid receptor ligands to modulate dependence-related behavioural effects of drugs like morphine and cocaine is well documented. The present study examined the effects of ␬-opioid agonists on nicotine-induced locomotor stimulation in rats chronically pre-exposed to nicotine (0.4 mg/kg/day). U50,488 [0.5–3 mg/kg subcutaneously (s.c.)], U69,593 [0.08–0.32 mg/kg intraperitoneally (i.p.)] and CI-977 (0.005–0.02 mg/kg s.c.) administered 30 min prior to nicotine (0.06, 0.2 and 0.4 mg/kg s.c.) dose-dependently antagonised its acute locomotor-activating effect, which was completely prevented by the highest tested dose of each agonist. Baseline activity was unaffected by the largest doses of U50,488 and U69,593, but it was reduced by 0.01 and 0.02 mg/kg of CI-977. The selective ␬-opioid receptor antagonist nor-BNI [30 µg intracerebroventricularly (i.c.v.)] blocked the effects of U69,593 on nicotine-induced behaviour, thus supporting the involvement of ␬-opioid receptors in this effect. In conclusion, the activation of ␬-opioid receptors clearly prevented nicotine-induced locomotor stimulation. The effects of at least two of the ␬-opioid agonists were not due to a general motor suppression. It is suggested that the mechanism entails a depression of nicotine-induced increases in accumbal dopamine by these compounds.
    [Show full text]
  • LPA1 Mediates Antidepressant-Induced ERK1/2 Signaling and Protection from Oxidative Stress in Glial Cells S
    Supplemental material to this article can be found at: http://jpet.aspetjournals.org/content/suppl/2016/09/07/jpet.116.236455.DC1 1521-0103/359/2/340–353$25.00 http://dx.doi.org/10.1124/jpet.116.236455 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS J Pharmacol Exp Ther 359:340–353, November 2016 Copyright ª 2016 by The American Society for Pharmacology and Experimental Therapeutics LPA1 Mediates Antidepressant-Induced ERK1/2 Signaling and Protection from Oxidative Stress in Glial Cells s Maria C. Olianas, Simona Dedoni, and Pierluigi Onali Laboratory of Cellular and Molecular Pharmacology, Section of Neurosciences and Clinical Pharmacology, Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy (M.C.O., S.D., P.O.) Received July 5, 2016; accepted September 6, 2016 ABSTRACT Downloaded from Antidepressants have been shown to affect glial cell functions abrogated by cell treatment with pertussis toxin and by and intracellular signaling through mechanisms that are still not the inhibition of fibroblast growth factor (FGF) receptor (FGF-R) completely understood. In the present study, we provide and platelet-derived growth factor receptor (PDGF-R) tyrosine evidence that in glial cells the lysophosphatidic acid (LPA) kinases. Both Ki16425 and AM966 suppressed antidepressant- receptor LPA1 mediates antidepressant-induced growth fac- induced phosphorylation of FGF-R. Moreover, blockade of tor receptor transactivation, ERK1/2 signaling, and protection LPA1 or inhibition of FGF-R and PDGF-R activities prevented b from oxidative stress. Thus, in C6 glioma cells and rat cortical antidepressant-stimulated Akt and GSK-3 phosphorylations. jpet.aspetjournals.org astrocytes, ERK1/2 activation induced by either amitriptyline or Mianserin protected C6 glioma cells and astrocytes from apopto- mianserin was antagonized by Ki16425 and VPC 12249 (S), tic cell death induced by H2O2, as indicated by increased cell which block LPA1 and LPA3 receptors, and by AM966, which viability, decreased expression of cleaved caspase 3, reduced selectively blocks LPA1.
    [Show full text]
  • [email protected]
    0022-3565/11/3362-488–495$20.00 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 336, No. 2 Copyright © 2011 by The American Society for Pharmacology and Experimental Therapeutics 173823/3659793 JPET 336:488–495, 2011 Printed in U.S.A. Buprenorphine and Opioid Antagonism, Tolerance, and Naltrexone-Precipitated Withdrawal Carol A. Paronis and Jack Bergman Preclinical Pharmacology Laboratory, McLean Hospital/Harvard Medical School, Belmont, Massachusetts (C.A.P, J.B.); and Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts (C.A.P.) Received August 6, 2010; accepted November 3, 2010 ABSTRACT The dual antagonist effects of the mixed-action ␮-opioid partial similarly determined at differing times (10 min to 48 h) after agonist/␬-opioid antagonist buprenorphine have not been pre- intramuscular injection. Overall, results show that buprenor- viously compared in behavioral studies, and it is unknown phine produced comparable 3- to 10-fold rightward shifts in whether they are comparably modified by chronic exposure. To the U50,488 dose-response curve under both acute and address this question, the dose-related effects of levorphanol, chronic conditions, but that chronic buprenorphine pro- trans-(Ϫ)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl] duced larger (10- to Ն30-fold) rightward shifts in the heroin benzeneacetamide (U50,488), heroin, and naltrexone on dose-effect function than observed acutely. Naltrexone de- food-maintained behavior in rhesus monkeys were studied creased operant responding in buprenorphine-treated mon- after acute and chronic treatment with buprenorphine (0.3 keys, and the position of the naltrexone dose-effect curve mg/kg/day). In acute studies, the effects of levorphanol and shifted increasingly to the left as the time after daily bu- U50,488 were determined at differing times after buprenor- prenorphine treatment increased from 10 min to 48 h.
    [Show full text]
  • Salvia Divinorum and Salvinorin A: an Update on Pharmacology And
    Oliver Grundmann Stephen M. Phipps Salvia divinorum and Salvinorin A: An Update on Immo Zadezensky Veronika Butterweck Pharmacology and Analytical Methodology Review Abstract derstand and elucidate the various medicinal properties of the plant itself and to provide the legislative authorities with enough Salvia divinorum (Lamiaceae) has been used for centuries by the information to cast judgement on S. divinorum. Mazatecan culture and has gained popularity as a recreational drug in recent years. Its potent hallucinogenic effects seen in Key words case reports has triggered research and led to the discovery of Salvia divinorum ´ Lamiaceae ´ depression ´ opioid antagonist ´ the first highly selective non-nitrogenous k opioid receptor ago- pharmacokinetics ´ pharmacology ´ toxicology ´ salvinorin A nist salvinorin A. This review critically evaluates the reported pharmacological and toxicological properties of S. divinorum Abbreviations and one of its major compounds salvinorin A, its pharmacokinet- CNS: central nervous system ic profile, and the analytical methods developed so far for its de- FST: forced swimming test tection and quantification. Recent research puts a strong empha- i.t.: intrathecal sis on salvinorin A, which has been shown to be a selective opioid KOR: kappa opioid receptor antagonist and is believed to have further beneficial properties, LSD: lysergic acid diethylamide rather than the leaf extract of S. divinorum. Currently animal norBNI: norbinaltorphimine studies show a rapid onset of action and short distribution and p.o.: per os 1039 elimination half-lives as well as a lack of evidence of short- or s.c.: subcutaneous long-term toxicity. Salvinorin A seems to be the most promising ssp.: subspecies approach to new treatment options for a variety of CNS illnesses.
    [Show full text]